Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Conditions
Interventions
PSB202
Locations
5
United States
Norton Cancer Institute
Louisville, Kentucky, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Epworth Healthcare
East Melbourne, Victoria, Australia
One Clinical research
Perth, Western Australia, Australia
Ruijin Hospital
Shanghai, China
Start Date
November 15, 2021
Primary Completion Date
July 1, 2023
Completion Date
January 1, 2024
Last Updated
March 28, 2022
NCT07545603
NCT06149286
NCT07387471
NCT06337318
NCT05006716
NCT06026319
Lead Sponsor
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions